Furthermore, recent studies have shown the predictive value of interferon (IFN)-γ signatures in the pathologic response to neoadjuvant immunotherapy in melanoma, which has led to interventional studies allocating patients to different neoadjuvant regimens according to IFNγ signatures20. The gene discussed is IFNG; the disease is melanoma.